Period:
Draw Mode:
| Volume | 64,830 |
|
|||||
| News | - | ||||||
| Day High | 1.4721 | Low High |
|||||
| Day Low | 1.4194 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| PaxMedica Inc | PXMD | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.0101 | -0.7% | 1.4299 | 19:53:23 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.42 | 1.4194 | 1.4721 | 1.44 | 1.44 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 330 | 64,830 | $ 1.44 | $ 93,082 | - | 1.2618 - 10.48 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:53:23 | formt | 143 | $ 1.4299 | USD |
PaxMedica Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 20.90M | 14.62M | 4.67M | $ - | $ - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | -269.46k | 1.90% |
PaxMedica News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PXMD Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.45 | 1.60 | 1.38 | 1.50 | 173,505 | -0.0201 | -1.39% |
| 1 Month | 1.57 | 1.75 | 1.2618 | 1.51 | 274,359 | -0.1401 | -8.92% |
| 3 Months | 1.96 | 2.85 | 1.2618 | 2.14 | 1,154,212 | -0.5301 | -27.05% |
| 6 Months | 2.30 | 4.07 | 1.2618 | 2.41 | 913,296 | -0.8701 | -37.83% |
| 1 Year | 6.50 | 10.48 | 1.2618 | 3.43 | 1,730,687 | -5.07 | -78.0% |
| 3 Years | 6.50 | 10.48 | 1.2618 | 3.43 | 1,730,687 | -5.07 | -78.0% |
| 5 Years | 6.50 | 10.48 | 1.2618 | 3.43 | 1,730,687 | -5.07 | -78.0% |
PaxMedica Description
| PaxMedica Inc an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). It focuses on the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and FXTAS. It is also focused on the treatment of Human African Trypanosomiasis (or HAT). Its candidate PAX-102, proprietary intranasal formulation of suramin, as well as other new chemical entities that are more targeted and highly selective antagonists of particular purinergic receptor subtypes. |